Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orca Bio is a late-stage biotechnology company developing high-precision allogeneic T-cell immunotherapies such as Orca-T and Orca-Q, with multicenter Phase 1, 2 and 3 trials in hematologic malignancies and autoimmune diseases; its lead program Orca-T is in a pivotal randomized Phase 3 trial versus standard allogeneic stem cell transplant in hematologic malignancies.[2][4]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Orcan Medical.